2022 ASCO|重磅研究摘要(LBA)公布!

中国首款自研P-CAB替戈拉生片获批 罗欣药业“创仿结合”战略迎新里程碑

2022 ASCO|重磅研究摘要(LBA)公布!

 

2022美国临床肿瘤学会(ASCO)盛会将于美国东部时间2022年6月3-7日举办。
今年ASCO有哪些重磅内容值得关注呢?
带您先览为快。

 

重磅LBA

LBA1 – Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.

报告时间(北京)

2022年6月6日 02:05 

LBA2 – Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).

报告时间(北京)

2022年6月6日 02:41 

LBA3 – Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.

报告时间(北京)

2022年6月6日 03:17 

LBA4 – Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.

报告时间(北京)

2022年6月6日 03:53 

LBA5 – Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.

报告时间(北京)

2022年6月5日 20:30 

 

乳腺癌

LBA1001 – Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.

报告时间(北京)

2022年6月5日 02:27

LBA1004 – A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.

报告时间(北京)

2022年6月5日 03:27

LBA501 – LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).

报告时间(北京)

2022年6月7日 22:45

 

肺癌

LBA8507 – SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).

报告时间(北京)

2022年6月5日 22:45

 

消化道肿瘤

LBA4011 – Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

报告时间(北京)

2022年6月4日 06:18 

LBA3505 – Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.

报告时间(北京)

2022年6月7日 00:09 

LBA3506 – FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or RAS/BRAFV600E-mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.

报告时间(北京)

2022年6月7日 00:45 

LBA3507 – Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases.

报告时间(北京)

2022年6月7日 00:57 

 

妇科肿瘤

LBA5500 – ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.

报告时间(北京)

2022年6月6日 21:00 

LBA5503 – Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

报告时间(北京)

2022年6月6日 22:00 

LBA5504 – Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).

报告时间(北京)

2022年6月6日 22:12 

 

泌尿生殖肿瘤

LBA4500 – EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

报告时间(北京)

2022年6月4日 03:45 

LBA4503 – CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer.

报告时间(北京)

2022年6月4日 04:45 

LBA5004 – Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

报告时间(北京)

2022年6月5日 22:00 

 

选取了部分入选LBA(Late Breaking Abstract)的重磅研究以飨读者,更多ASCO的研究报道,敬请持续关注!

中国首款自研P-CAB替戈拉生片获批 罗欣药业“创仿结合”战略迎新里程碑版权声明/免责声明
本文为授权转载文章,版权归拥有者。
仅供感兴趣的个人谨慎参考,非商用,非医用、非投资用。
欢迎朋友们批评指正!衷心感谢!
文中图片、视频为授权正版作品,或来自微信公共图片库,或取自网络
根据CC0协议使用,版权归拥有者。
任何问题,请与我们联系(电话:13651980212。微信:27674131。邮箱:contact@drugtimes.cn)。衷心感谢!
2022 ASCO|重磅研究摘要(LBA)公布!

推荐阅读

 

2022 ASCO|重磅研究摘要(LBA)公布!
2022 ASCO|重磅研究摘要(LBA)公布!点击这里,帮您找到理想的合作伙伴

本篇文章来源于微信公众号:药时代

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2022年4月29日 20:24
下一篇 2022年4月29日 20:24

相关推荐

公众号
公众号
分享本页
返回顶部
FDA批准首款NASH/MASH新药,中国药企如何分享这个百亿美元大蛋糕?点击观看直播